ライフサイエンスコーパス: mycophenolate

1 mtuzumab/tacrolimus or daclizumab/tacrolimus/mycophenolate.

2 immunosuppression consists of tacrolimus and mycophenolate.

3 methylprednisolone infusions, prednisone and mycophenolate.

4 with or without a calcineurin inhibitor and mycophenolate.

5 nts were treated with prednisone 1 mg/kg and mycophenolate 2 g daily.

6 Immunosuppression was escalated to mycophenolate 3 g daily, with addition of a second agent

7 used immunosuppressive agents tacrolimus and mycophenolate, albeit with appropriate dose adjustment.

8 Here we found that mycophenolate, an inhibitor of de novo guanine nucleotid

9 e for scleroderma overlap syndromes, whereas mycophenolate and azathioprine are also used for both sk

10 ression of RAIDs (i.e. rituximab, belimumab, mycophenolate and azathioprine).

11 induction and maintenance with sirolimus or mycophenolate and BELA (n=5) or EFA (n=5).

12 ed by the continuation of, or conversion to, mycophenolate and compared with standard or higher dose

13 The oral immunosuppressive drugs used were mycophenolate and cyclophosphamide.

14 unosuppression, with concomitant tacrolimus, mycophenolate and standard dose daclizumab (SB group) or

15 ; accumulation of data supporting the use of mycophenolate and tacrolimus as second-line treatment; a

16 pients received calcineurin inhibitor (CNI), mycophenolate, and posttransplant cyclophosphamide for g

17 tation in recipients receiving prednisolone, mycophenolate, and tacrolimus.

18 Initial treatment with rituximab, mycophenolate, and, to a lesser degree, azathioprine sig

19 spectrum disorder treated with azathioprine, mycophenolate, and/or rituximab at the Mayo Clinic and t

20 methotrexate, azathioprine, leflunomide, and mycophenolate, are often used as alternatives to steroid

21 nisolone with cyclosporine, azathioprine, or mycophenolate as steroid-sparing agents.

22 nistered standardized basiliximab-tacrolimus-mycophenolate-corticosteroid immunosuppressive therapy,

23 suggest a need to escalate therapy to higher mycophenolate doses, and in one fifth of cases to add a

24 (early azathioprine era: 1990-2000 vs modern mycophenolate era: 2000-2011).

25 in 4627 children who received tacrolimus and mycophenolate immunosuppression and did not have multior

26 in consecutive recipients taking tacrolimus/mycophenolate immunosuppression at a single center.

27 , donor hematopoietic stem cells, tacrolimus/mycophenolate immunosuppression converted to sirolimus,

28 closporine was combined with azathioprine or mycophenolate in cases unresponsive to only 1 of these d

29 combining atorvastatin with cyclosporine or mycophenolate in place of rapamycin was ineffective.

30 different mouse models of HSCR, addition of mycophenolate increased the penetrance and severity of H

31 S precursor proliferation most likely causes mycophenolate-induced migration defects and aganglionosi

32 To the best of our knowledge, mycophenolate is the first medicine identified that caus

33 emtuzumab (C1H) induction and tacrolimus and mycophenolate maintenance with switch to sirolimus and w

34 ded, and recently two agents, budesonide and mycophenolate mofeteil, show promise in treating AIH.

35 ly for 2 days) and GVHD immunoprophylaxis of mycophenolate mofetil (1 g three times a day, days 0-28)

36 , total body irradiation, cyclosporine A and mycophenolate mofetil (12 doses), and antilymphocyte ser

37 , double-dummy, phase 3 study comparing oral mycophenolate mofetil (2 g per day) and oral azathioprin

38 Post grafting immunosuppression consisted of mycophenolate mofetil (28 days) and cyclosporine (35 day

39 vents was higher with azathioprine than with mycophenolate mofetil (39.6% vs. 25.2%, P = 0.02).

40 or tacrolimus and an antimetabolite, mostly mycophenolate mofetil (91.7%).

41 nation therapy with IFN-beta-1a (Avonex) and mycophenolate mofetil (Cellcept) modulated the hyperphos

42 y kidney transplant recipients receiving 2 g mycophenolate mofetil (group A, n=75) versus 1.440 g ent

43 Immunosuppression included mycophenolate mofetil (MMF) (2 g/day), tacrolimus (targe

44 or 3.0 mg with reduced-dose cyclosporine, or mycophenolate mofetil (MMF) 3 g/day with standard-dose c

45 Mycophenolate mofetil (MMF) and combination therapies in

46 Prophylactic drugs, such as mycophenolate mofetil (MMF) and cyclosporine A (CsA), ar

47 acrolimus (TAC) or cyclosporine A (CsA) with mycophenolate mofetil (MMF) and steroids after heart tra

48 ceiving tacrolimus (Tac) in combination with mycophenolate mofetil (MMF) and those maintained on a re

49 -coated mycophenolate sodium (EC-MPS) versus mycophenolate mofetil (MMF) and to examine the impact of

50 Nowadays, tacrolimus (Tac) and mycophenolate mofetil (MMF) are considered more efficien

51 atical model using T- and B-cell markers and mycophenolate mofetil (MMF) dosage.

52 id corticosteroid withdrawal, tacrolimus and mycophenolate mofetil (MMF) for 1 month followed by rand

53 Clinicians are increasingly using mycophenolate mofetil (MMF) for the treatment of systemi

54 d with tacrolimus (Tac) and dose-intensified mycophenolate mofetil (MMF) further adjusted individuall

55 calcineurin inhibitor (CNI) withdrawal with mycophenolate mofetil (MMF) has not become routine pract

56 Rapamycin and mycophenolate mofetil (MMF) have been used for maintenan

57 e evidence of favorable long-term effects of mycophenolate mofetil (MMF) in renal transplantation, it

58 well as to characterize dose adjustments of mycophenolate mofetil (MMF) in this setting.

59 ebo-controlled study of daclizumab (DZB) and mycophenolate mofetil (MMF) including DZB(+)MMF(+), DZB(

60 nzyme activity and adverse effects caused by mycophenolate mofetil (MMF) inhibition may be geneticall

61 The use of mycophenolate mofetil (MMF) is associated with less acut

62 The prodrug ester mycophenolate mofetil (MMF) is frequently used in solid-

63 -coated mycophenolate sodium (EC-MPS) versus mycophenolate mofetil (MMF) maintenance immunosuppressio

64 ssigned 1:1 on day 28 posttransplantation to mycophenolate mofetil (MMF) or Everolimus combined with

65 -blinded trial, was designed to test whether mycophenolate mofetil (MMF) plus corticosteroids was sup

66 Mycophenolate mofetil (MMF) side effects often prompt do

67 st basiliximab induction with tacrolimus and mycophenolate mofetil (MMF) therapy in renal transplanta

68 el studies demonstrated that conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenol

69 Rodnan skin score (MRSS) improvement during mycophenolate mofetil (MMF) treatment.

70 udy was to assess the effects of late CNI or mycophenolate mofetil (MMF) withdrawal on ambulatory blo

71 We examined the effects of late CNI or mycophenolate mofetil (MMF) withdrawal on echocardiograp

72 rd maintenance dosing with tacrolimus (TAC), mycophenolate mofetil (MMF), and corticosteroids.

73 to compare tacrolimus/sirolimus, tacrolimus/mycophenolate mofetil (MMF), and cyclosporine/sirolimus.

74 xamined the association of tacrolimus (TAC), mycophenolate mofetil (MMF), and prednisone with BKN in

75 icularly with the combination of tacrolimus, mycophenolate mofetil (MMF), and steroids.

76 All patients were initially treated with mycophenolate mofetil (MMF), cyclosporine A (CsA), and p

77 rolled trial comparing early CW (tacrolimus, mycophenolate mofetil (MMF), daclizumab, and corticoster

78 ines were treated with the immunosuppressant mycophenolate mofetil (MMF).

79 ng maintenance with both corticosteroids and mycophenolate mofetil (MMF).

80 eated with the combination of tacrolimus and mycophenolate mofetil (MMF).

81 event rates for EC-MPS were comparable with mycophenolate mofetil (MMF).

82 itor (CNI) with either methotrexate (MTX) or mycophenolate mofetil (MMF).

83 drug and a calcineurin inhibitor as follows: mycophenolate mofetil (MMF)/mycophenolate sodium+tacroli

84 eived tacrolimus (FK-506, 0.1 mg/kg per day)/mycophenolate mofetil (MMF, 60 mg/kg per day), and anti-

85 ip), tacrolimus (FK506; 0.1-0.5-1 mg/kg ip), mycophenolate mofetil (MMF; 60-120-300 mg/kg oral) or ve

86 ficacy and safety of a 1-year treatment with mycophenolate mofetil (MMF; target plasma mycophenolic a

87 ts were assigned to azathioprine (n = 80) or mycophenolate mofetil (n = 76) and were followed up for

88 42 patients were randomly assigned to either mycophenolate mofetil (n=69) or cyclophosphamide (n=73).

89 tment success with methotrexate and 47% with mycophenolate mofetil (P = 0.09).

90 ), and higher mean tacrolimus (P=0.0009) and mycophenolate mofetil (P=0.01) blood levels.

91 d to azathioprine (starting at 2 mg/kg/d) or mycophenolate mofetil (starting at 2000 mg/d) after indu

92 mmy, centre-blocked design to receive either mycophenolate mofetil (target dose 1500 mg twice daily)

93 itor-withdrawn, sirolimus 8 to 12 ng/mL with mycophenolate mofetil 2 g two times per day.

94 126 patients (mycophenolate mofetil [n=63] and cyclophosphamide [n=63]

95 olimus/basiliximab [Tac/Bas], 139 tacrolimus/mycophenolate mofetil [Tac/MMF], and 139 tacrolimus/MMF/

96 g enteric-coated mycophenolate sodium versus mycophenolate mofetil along with reduced maintenance tac

97 d prolonged-release tacrolimus, basiliximab, mycophenolate mofetil and 1 bolus of intraoperative cort

98 16 (11%) patients died (five [7%] mycophenolate mofetil and 11 [15%] cyclophosphamide), wi

99 ly assigned to maintenance treatment (116 to mycophenolate mofetil and 111 to azathioprine).

100 Postgrafting immunosuppression included mycophenolate mofetil and a calcineurin inhibitor.

101 aCD20 antibody, followed by maintenance with mycophenolate mofetil and an intensively dosed alphaCD40

102 Large controlled trials using mycophenolate mofetil and azathioprine for maintenance t

103 e that conventional immunomodulators such as mycophenolate mofetil and biologics such as rituximab ar

104 QD 0.3 mg/kg per day (Arm 3; n=304) all with mycophenolate mofetil and corticosteroids (tapered) over

105 regimens or placebo, both on a background of mycophenolate mofetil and corticosteroids.

106 the % FVC improved significantly in both the mycophenolate mofetil and cyclophosphamide groups.

107 her abatacept or placebo, on a background of mycophenolate mofetil and glucocorticoids.

108 All patients received cyclosporine and mycophenolate mofetil and gradually tapered prednisone.

109 nt and graft survivals after introduction of mycophenolate mofetil and induction with basiliximab.

110 was no clear difference in efficacy between mycophenolate mofetil and intravenous cyclophosphamide i

111 e active immunosuppressive substance in both mycophenolate mofetil and mycophenolate sodium, and it i

112 ll case series suggest that a combination of mycophenolate mofetil and prednisone may be an effective

113 On the background of negative trials with mycophenolate mofetil and rituximab, there are recent da

114 low and even no oral steroids can be used in mycophenolate mofetil and rituximab-based regimes.

115 ave unexpected ALPS-specific toxicities, and mycophenolate mofetil and sirolimus have been demonstrat

116 d with 30% to 50% reduction in doses of both mycophenolate mofetil and Tac without antiviral therapy.

117 on and SF immunosuppression with maintenance mycophenolate mofetil and tacrolimus between October 200

118 py with a T cell-depleting agent followed by mycophenolate mofetil and tacrolimus is presently the mo

119 Mycophenolate mofetil and TNF-alpha antagonists can be u

120 All patients received tacrolimus and mycophenolate mofetil and underwent a 5-day glucocortico

121 ly oral methotrexate or 1 g twice daily oral mycophenolate mofetil and were monitored monthly for 6 m

122 inhibitor (CNI) dose or conversion to either mycophenolate mofetil and/or rapamycin resulted in varia

123 Both MPA and mycophenolate mofetil are highly specific inhibitors of

124 Calcineurin inhibitors and mycophenolate mofetil are potential salvage therapies, a

125 ting immunosuppression with cyclosporine and mycophenolate mofetil as a control group, we compared ou

126 Clinical trials evaluating mycophenolate mofetil as remission induction therapy, gu

127 Mycophenolate mofetil at intensified and individually ad

128 h enteric-coated mycophenolate sodium versus mycophenolate mofetil at month 6 among African Americans

129 lung disease, and the present preference for mycophenolate mofetil because of its better tolerability

130 ther reduced calcineurin inhibitor (CNI) and mycophenolate mofetil by 30% to 50% (n=23), or we switch

131 lonal antibody induction with tacrolimus and mycophenolate mofetil combination maintenance, both regi

132 SRL+mycophenolate mofetil versus tacrolimus+mycophenolate mofetil de novo, and (d) conversion from C

133 Mycophenolate mofetil did not provide mycophenolic acid

134 Mycophenolate mofetil dose reduction was independently a

135 dose equal to or more than 2000 mg per day (mycophenolate mofetil equivalents) was significantly hig

136 Tacrolimus or sirolimus and mycophenolate mofetil exposure was identical between gro

137 derma-related interstitial lung disease with mycophenolate mofetil for 2 years or cyclophosphamide fo

138 l effectiveness of both cyclophosphamide and mycophenolate mofetil for progressive scleroderma-relate

139 Relapses were more common in the mycophenolate mofetil group (42/76 patients) compared wi

140 ed from baseline to 24 months by 2.19 in the mycophenolate mofetil group (95% CI 0.53-3.84) and 2.88

141 e adverse events in 8 patients (7.5%) in the mycophenolate mofetil group (HR, 0.53 [95% CI, 0.23-1.18

142 thioprine group and in 23.5% of those in the mycophenolate mofetil group (P = 0.11), and the rate of

143 ilure were 16.4% (19 of 116 patients) in the mycophenolate mofetil group and 32.4% (36 of 111) in the

144 Mycophenolate mofetil has emerged as a viable alternativ

145 Mycophenolate mofetil has not become the "wonder drug" t

146 ptopurine (OR, 0.62; 95% CI, 0.15-2.53), and mycophenolate mofetil hydrochloride (OR, 0.66; 95% CI, 0

147 same conditioning regimen with sirolimus and mycophenolate mofetil immune suppression.

148 llowed by a short course of cyclosporine and mycophenolate mofetil immunosuppression.

149 olonged-release tacrolimus, basiliximab, and mycophenolate mofetil immunosuppressive regimen is effic

150 solimumab nonimprovers were downregulated in mycophenolate mofetil improvers, suggesting that immunom

151 We compared Everolimus versus mycophenolate mofetil in an investigator-initiated singl

152 are recent data demonstrating superiority of mycophenolate mofetil in certain subgroups.

153 ted case reports of the use of rituximab and mycophenolate mofetil in resistant disease.

154 Mycophenolate mofetil is a potent immunosuppressant medi

155 l studies suggest that the immunosuppressant mycophenolate mofetil is associated with anemia.

156 hymocyte globulin induction, tacrolimus, and mycophenolate mofetil is associated with excellent patie

157 ith interstitial lung disease (ILD), whereas mycophenolate mofetil is effective in both polymyositis

158 tides (IMPROVE), to test the hypothesis that mycophenolate mofetil is more effective than azathioprin

159 Prednisolone, tacrolimus, and mycophenolate mofetil modified fecal microbiota at the f

160 s), with an unadjusted hazard ratio (HR) for mycophenolate mofetil of 1.69 (95% confidence interval [

161 The effect of sirolimus or mycophenolate mofetil on NK cells was minimal.

162 nts received systemic immunosuppression with mycophenolate mofetil or cyclosporine A.

163 had worsened gastrointestinal symptoms with mycophenolate mofetil or EC-MPS in combination with Tac

164 The maintenance regimen of tacrolimus and mycophenolate mofetil or mycophenolate sodium was associ

165 =0.003) than the regimen of cyclosporine and mycophenolate mofetil or mycophenolate sodium.

166 Whether treatments such as mycophenolate mofetil or statins have a role in preventi

167 antithymocyte globulin induction followed by mycophenolate mofetil plus calcineurin inhibitors (n=28,

168 uded maintenance therapy with belatacept and mycophenolate mofetil plus induction with basiliximab an

169 adults who were randomized to cyclosporin or mycophenolate mofetil plus pulse oral dexamethasone with

170 uccess in transitioning to azathioprine from mycophenolate mofetil prior to pregnancy in patients wit

171 l randomized controlled trial, International Mycophenolate Mofetil Protocol to Reduce Outbreaks of Va

172 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study was a

173 Fewer patients on mycophenolate mofetil than on cyclophosphamide premature

174 Combined prednisone and mycophenolate mofetil therapy is a potentially effective

175 Switching from mycophenolate mofetil to leflunomide successfully cleare

176 molluscum contagiosum who were switched from mycophenolate mofetil to leflunomide.

177 It compared the addition of mycophenolate mofetil to steroids vs steroids/placebo to

178 for 2 weeks after each infusion); rapamycin+mycophenolate mofetil treatment as maintenance therapy.

179 Immunosuppressant mycophenolate mofetil treatment of enriched IL-17A(+) ce

180 either 25 mg oral methotrexate weekly or 1 g mycophenolate mofetil twice daily, with a corticosteroid

181 Finally, delaying cyclosporine and mycophenolate mofetil until after MTX administration did

182 IS consisted of ATG, anti-CD154mAb, and mycophenolate mofetil until age 8 to 12 months.

183 while low DNAemia rates were associated with mycophenolate mofetil use (p < 0.0001) and EBV viral cap

184 acrolimus elimination at 3 months versus SRL+mycophenolate mofetil versus tacrolimus+mycophenolate mo

185 Mycophenolate mofetil was associated with PCP risk only

186 Although mycophenolate mofetil was better tolerated and associate

187 Mycophenolate mofetil was initiated postoperatively with

188 Use of mycophenolate mofetil was inversely associated with vacc

189 Among patients with AAV, mycophenolate mofetil was less effective than azathiopri

190 , the addition of a calcineurin inhibitor or mycophenolate mofetil was predictive for maintaining a D

191 Mycophenolate mofetil was superior to azathioprine in ma

192 Mycophenolate mofetil was superior to azathioprine with

193 Mycophenolate mofetil was the treatment in 10 patients,

194 Thymoglobulin induction, tacrolimus, and mycophenolate mofetil were also associated.

195 Tacrolimus and mycophenolate mofetil were required as well as either ra

196 ab 1 month before transplant; tacrolimus and mycophenolate mofetil were started 1 week before surgery

197 A calcineurin inhibitor and mycophenolate mofetil were used for postgrafting immunos

198 enance immunosuppression with tacrolimus and mycophenolate mofetil with/without steroids.

199 mmunosuppression consisted of tacrolimus and mycophenolate mofetil without induction or depletional t

200 We hypothesised that a 2 year course of mycophenolate mofetil would be safer, better tolerated,

201 A total of 67 patients (35 methotrexate, 32 mycophenolate mofetil) contributed to the primary outcom

202 e 5'-monophosphate dehydrogenase inhibitors (mycophenolate mofetil) to the immunosuppressive armament

203 ive oral methotrexate, 25 mg weekly, or oral mycophenolate mofetil, 1 g twice daily, and were followe

204 Tacrolimus, 4 mg/d, and mycophenolate mofetil, 1.0 g/d, versus intravenous cyclo

205 dnisone, 40 mg/d, tapered over 6 months, and mycophenolate mofetil, 1000 mg twice daily, for a mean o

206 preva Lupus Management Study (ALMS) trial of mycophenolate mofetil, 3) the Lupus Nephritis Assessment

207 es (95% CI: 0.6, 9.8; P = .20) the odds with mycophenolate mofetil, a difference that was not statist

208 nolic acid (MPA) is the active metabolite of mycophenolate mofetil, an effective immunosuppressive dr

209 plored for this disease including Rituximab, mycophenolate mofetil, and adrenocorticotropic hormone,

210 All subjects received basiliximab induction, mycophenolate mofetil, and corticosteroids.

211 or induction in combination with tacrolimus, mycophenolate mofetil, and corticosteroids.

212 sone tapered off over 6 days, thymoglobulin, mycophenolate mofetil, and cyclosporine A (CsA).

213 ter transplantation consisted of tacrolimus, mycophenolate mofetil, and glucocorticoids.

214 emotherapies cyclophosphamide, azathioprine, mycophenolate mofetil, and methotrexate.

215 ldren with SLE received cyclophosphamide and mycophenolate mofetil, and more children with JIA receiv

216 ppressive regime consisting of cyclosporine, mycophenolate mofetil, and prednisolone were well tolera

217 ept or tacrolimus combined with basiliximab, mycophenolate mofetil, and prednisolone.

218 te globulin, methylprednisolone, tacrolimus, mycophenolate mofetil, and prednisone were commenced.

219 d rabbit antithymocyte globulin, tacrolimus, mycophenolate mofetil, and prednisone.

220 ntithymocyte globulin induction, tacrolimus, mycophenolate mofetil, and steroid withdrawal by day 5 a

221 tithymocyte globulin, calcineurin inhibitor, mycophenolate mofetil, and steroids.

222 ion therapy, in combination with tacrolimus, mycophenolate mofetil, and steroids.

223 ndardized immunosuppression with tacrolimus, mycophenolate mofetil, and steroids.

224 ttransplantation high-dose cyclophosphamide, mycophenolate mofetil, and tacrolimus or sirolimus.

225 nance immunosuppression was with prednisone, mycophenolate mofetil, and tacrolimus.

226 ing, T-cell-replete allografting, then PTCy, mycophenolate mofetil, and tacrolimus.

227 eks, or tacrolimus QD 0.2 mg/kg per day with mycophenolate mofetil, basiliximab, and corticosteroids

228 ee immunosuppressive regimen, when used with mycophenolate mofetil, corticosteroids, and anti-interle

229 her a CNI-free regimen, including sirolimus, mycophenolate mofetil, corticosteroids, and anti-interle

230 ntenance therapy, often with azathioprine or mycophenolate mofetil, is required to consolidate remiss

231 henolic acid (MPA), the active metabolite of mycophenolate mofetil, on erythropoiesis in vitro.

232 unosuppressive protocol included tacrolimus, mycophenolate mofetil, prednisone, and antithymocyte glo

233 pressive treatment that included tacrolimus, mycophenolate mofetil, prednisone, and, for induction, a

234 temic sclerosis treated with five therapies: mycophenolate mofetil, rituximab, abatacept, nilotinib,

235 Monitored drugs were mycophenolate mofetil, sirolimus, or azathioprine.

236 were treated for 14 days with prednisolone, mycophenolate mofetil, tacrolimus, a combination of thes

237 hen given in combination with tacrolimus and mycophenolate mofetil, was first demonstrated after nonm

238 ession with oral tacrolimus, prednisone, and mycophenolate mofetil, which has continued until the pre

239 deceased donor KTRs maintained on tacrolimus/mycophenolate mofetil-based regimen along with steroid.

240 sitivity, hepatitis C virus reinfection, and mycophenolate mofetil-free regimens were significant ris

241 l islet grafts under anti-thymocyte globulin-mycophenolate mofetil-tacrolimus protocol.

242 d thymoglobulin, tacrolimus, prednisone, and mycophenolate mofetil.

243 ts were randomized to methotrexate and 39 to mycophenolate mofetil.

244 n between patients receiving methotrexate or mycophenolate mofetil.

245 eiving calcineurin inhibitors, steroids, and mycophenolate mofetil.

246 erious effects of rapamycin, tacrolimus, and mycophenolate mofetil.

247 estimated GFR, male sex, and treatment with mycophenolate mofetil.

248 imen consisting of tacrolimus, steroids, and mycophenolate mofetil.

249 revented by immunosuppression with FK506 and mycophenolate mofetil.

250 pression, all dogs received cyclosporine and mycophenolate mofetil.

251 ften in patients given cyclophosphamide than mycophenolate mofetil.

252 FK506 but can be blocked by the presence of mycophenolate mofetil.

253 rrow infusion then steroids, tacrolimus, and mycophenolate mofetil.

254 e immunosuppression (IS) with tacrolimus and mycophenolate mofetil.

255 ence proteinuria responses to cyclosporin or mycophenolate mofetil/dexamethasone.

256 , tacrolimus (FK), cyclosporine A (CSA), and mycophenolate mofetil/sodium (MMF).

257 d were discharged on a calcineurin inhibitor/mycophenolate mofetil/steroid-free immunosuppression.

258 cipients maintained on calcineurin inhibitor/mycophenolate mofetil/steroid-free regimen.

259 oglobulin/interleukin 2 receptor blocker and mycophenolate mofetil/tacrolimus (Tac)/prednisone was em

260 ts were randomized to methotrexate and 16 to mycophenolate mofetil; 30 had acute VKH.

261 The no-ATG group received mycophenolate mofetile + cyclosporin A as graft-versus-h

262 Recommendations are impossible for mycophenolate, montelukast, intravenous immunoglobulins,

263 galovirus [CMV]) in KTR on sirolimus (SRL) + mycophenolate (MPA) or SRL + tacrolimus (Tac), relative

264 hs posttransplant among everolimus (EVR) and mycophenolate (MPA) treatment arms and used a time-depen

265 cubated with serial dilutions of tacrolimus, mycophenolate (MPA), sirolimus, tofacitinib, and belatac

266 ves (octyl mycophenolate, MPA-C8E; octadecyl mycophenolate, MPA-C18E; and octadecyl mycophenolamide,

267 Alkyl chain derivatives (octyl mycophenolate, MPA-C8E; octadecyl mycophenolate, MPA-C18

268 onor transplant recipients received CNI with mycophenolate or methotrexate for GVHD prophylaxis; 1245

269 transplant-related drugs such as tacrolimus, mycophenolate, or antithymocyte globulin go on shortage.

270 e regimens including tacrolimus (P=0.001) or mycophenolate (P=0.0025).

271 eiving reduced TAC exposure, prednisone, and mycophenolate, randomized at 3 months to be converted or

272 Mycophenolate reduced the relapse rate by up to 87.4%, w

273 Pediatrics, nontacrolimus/mycophenolate regimens, and nonrenal transplants were ex

274 We studied the association between mycophenolate-related anemia and leukopenia and 2724 sin

275 Mycophenolate-related anemia and leukopenia are well-kno

276 est that genetics may play a role in risk of mycophenolate-related hematologic toxicity.

277 yclosporin, tacrolimus (Tac), enteric-coated mycophenolate sodium (EC-MPS) and sirolimus (SRL) in ora

278 ycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) significantly reduces gast

279 omes of patients who received enteric-coated mycophenolate sodium (EC-MPS) versus mycophenolate mofet

280 ions in patients treated with enteric-coated mycophenolate sodium (EC-MPS) versus mycophenolate mofet

281 Although enteric-coated mycophenolate sodium (EC-MPS) was developed to reduce ga

282 uced tacrolimus dosing (rTd), enteric-coated mycophenolate sodium (EC-MPS), and early corticosteroid

283 tudy, the IEM was combined to enteric-coated mycophenolate sodium (ECMPS).

284 group A, n=75) versus 1.440 g enteric-coated mycophenolate sodium (group B, n=75), with reduced maint

285 with prednisolone, cyclosporine A (CsA), and mycophenolate sodium (MPS) for the first 6 months after

286 AE in patients receiving everolimus (EVR) or mycophenolate sodium (MPS).

287 m, randomized trial comparing enteric-coated mycophenolate sodium versus mycophenolate mofetil along

288 was significantly higher with enteric-coated mycophenolate sodium versus mycophenolate mofetil at mon

289 n of tacrolimus and mycophenolate mofetil or mycophenolate sodium was associated with 25% greater odd

290 itor as follows: mycophenolate mofetil (MMF)/mycophenolate sodium+tacrolimus (TAC), MMF+cyclosporine

291 substance in both mycophenolate mofetil and mycophenolate sodium, and it is widely used after organ

292 of cyclosporine and mycophenolate mofetil or mycophenolate sodium.

293 2ra versus no induction using tacrolimus and mycophenolate (TAC/MPA)-based therapy.

294 We studied 151 living-donor, tacrolimus/mycophenolate-treated recipients without overt risk fact

295 Mycophenolate treatment also reduced ENS precursor migra

296 In mice, mycophenolate treatment selectively impaired ENS precurs

297 raft loss at 5 years, whereas tacrolimus and mycophenolate use was associated with reduced risk (RR,

298 The average dose (+/-SD) of mycophenolate was 1.42 +/- 0.3 g/day and the individual

299 ate analysis showed that only the absence of mycophenolate was associated with a better vaccine respo

300 unosuppression, consisting of tacrolimus and mycophenolate, was weaned over 1 year.